Arcturus Therapeutics Ltd (NASDAQ:ARCT) has been given a consensus recommendation of “Buy” by the seven brokerages that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, four have given a buy recommendation and one has assigned a strong buy recommendation to the company.
A number of equities research analysts have weighed in on the stock. Zacks Investment Research cut shares of Arcturus Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, January 8th. Laidlaw started coverage on shares of Arcturus Therapeutics in a research note on Tuesday, February 19th. They issued a “buy” rating for the company. ValuEngine downgraded shares of Arcturus Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, December 21st. Finally, Roth Capital reiterated a “buy” rating on shares of Arcturus Therapeutics in a research report on Wednesday.
Shares of NASDAQ:ARCT traded down $0.18 during midday trading on Tuesday, hitting $4.87. The company’s stock had a trading volume of 91,225 shares, compared to its average volume of 42,836. The company has a market cap of $52.32 million, a P/E ratio of -1.38 and a beta of 2.14. Arcturus Therapeutics has a 12-month low of $4.11 and a 12-month high of $10.00.
Large investors have recently modified their holdings of the business. Worth Venture Partners LLC acquired a new stake in shares of Arcturus Therapeutics during the third quarter worth approximately $290,000. ARK Investment Management LLC lifted its stake in Arcturus Therapeutics by 45.0% in the third quarter. ARK Investment Management LLC now owns 773,772 shares of the biotechnology company’s stock valued at $6,840,000 after buying an additional 239,999 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in Arcturus Therapeutics by 91.7% in the third quarter. JPMorgan Chase & Co. now owns 16,744 shares of the biotechnology company’s stock valued at $148,000 after buying an additional 8,008 shares during the last quarter. Finally, BlackRock Inc. bought a new stake in shares of Arcturus Therapeutics during the second quarter valued at about $169,000. 10.29% of the stock is owned by institutional investors.
Arcturus Therapeutics Company Profile
Arcturus Therapeutics Ltd., an RNA medicines company, develops nucleic acid medicines to treat diseases with unmet medical needs. Its RNA therapeutics platforms could be applied in various types of RNA medicines, including small interfering RNA, messenger RNA, replicon RNA, antisense RNA, microRNA, and gene editing therapeutics.
Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.